NXY-059

NXY-059 is a neuroprotective agent that was investigated for the treatment of acute ischemic stroke. It functions as a free radical-trapping agent, specifically designed to neutralize harmful free radicals that contribute to secondary neurological damage following stroke. ## Mechanism of Action NXY-059 is a nitrone-based compound that works by trapping free radicals generated during ischemic events. In stroke, the initial damage from oxygen deprivation is followed by secondary injury caused by free radicals and oxidative stress. NXY-059 was developed to interrupt this cascade by neutralizing these harmful molecules[1][4]. The drug may be more accurately described as "vasculoprotective" rather than purely neuroprotective, as it appears to act primarily on the vascular component of the neurovascular unit[2]. This mechanism was thought to potentially preserve brain tissue that would otherwise be damaged following a stroke. ## Clinical Development NXY-059 underwent extensive clinical testing through the SAINT (Stroke-Acute Ischemic-NXY Treatment) trial program: - **SAINT I**: This Phase IIb/III trial showed initially promising results, with a statistically significant reduction in disability after acute stroke compared to placebo[1][3]. The primary outcome measure was a "shift" in the modified Rankin Scale (mRS), which measures disability[2]. - **SAINT II**: This follow-up Phase III trial, however, failed to confirm the positive results of SAINT I. The combined analysis of both trials showed that NXY-059 was ineffective for the treatment of acute ischemic stroke within 6 hours of symptom onset[4]. ## Administration and Safety Profile NXY-059 was administered as an intravenous infusion over 72 hours, which some considered cumbersome for patients with milder strokes who might not remain hospitalized that long[2]. The drug demonstrated a predictable pharmacokinetic profile and primarily underwent renal elimination, requiring dose adjustments in patients with renal insufficiency[1]. The safety profile of NXY-059 was generally favorable. In clinical trials: - Fewer NXY-059 patients than placebo patients discontinued treatment due to adverse events - Hypokalemia during infusion was the only notable adverse event (10.1% vs 7.5% for placebo)[2][4] - No serious adverse events requiring special monitoring were identified, except for drug accumulation in patients with renal insufficiency[1] ## Interaction with Thrombolytic Therapy An interesting finding from post-hoc analysis of the SAINT I trial was that NXY-059 appeared to reduce the rate of symptomatic intracerebral hemorrhage in patients who also received tissue plasminogen activator (tPA) from 6.4% to 2.5%[2]. This suggested a potential role for NXY-059 as an adjunct to thrombolytic therapy, possibly by affecting matrix metalloproteinase 9 (MMP-9) activity, which is associated with tPA-related hemorrhage[2]. ## Preclinical Evidence and Limitations In animal models of stroke, NXY-059 showed reductions in infarct volume and neurologic deficits[1]. However, subsequent analysis of the preclinical data revealed several shortcomings: - A systematic review found that the reported efficacy of NXY-059 in animal models was confounded by low study quality[6] - Only 2 of 9 publications reported randomization, concealment of treatment allocation, and blinded outcome assessment - Studies not reporting these quality items gave substantially higher estimates of efficacy than higher-quality studies[6] Critics have argued that the preclinical evaluation of NXY-059 lacked rigorous testing and failed to demonstrate reproducible protection in extended time windows across clinically relevant stroke models at multiple research laboratories[8]. ## Current Status Following the negative results of the SAINT II trial, NXY-059 is no longer being pursued for the treatment of acute ischemic stroke. The failure of this drug, despite promising preclinical data, has highlighted the challenges in translating neuroprotective therapies from bench to bedside and has led to calls for improved standards in the design, conduct, and reporting of animal studies in stroke research[6][8].

Other names

2,4-disulfophenyl-PBNNXY-059NXY059NXY 059disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide